NCT06919016View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

March 25, 2027

Study Completion Date

March 25, 2027

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

DV700P-RNA

Intramuscular (IM) injection

BIOLOGICAL

DV701B1.1-RNA

IM injection

Trial Locations (8)

10032

RECRUITING

Columbia P&S CRS (Site ID: 30329), New York

14642

NOT_YET_RECRUITING

University of Rochester Medical Center (Site ID: 31467), Rochester

15213

NOT_YET_RECRUITING

University of Pittsburgh (Site ID: 1001), Pittsburgh

30030

RECRUITING

The Hope Clinic of the Emory Vaccine Center CRS (Site ID: 31440), Decatur

35222

RECRUITING

University of Alabama Medical Center (Site ID: 31788), Birmingham

37232

RECRUITING

Vanderbilt University Medical Center (Site ID: 30352), Nashville

98104

RECRUITING

Seattle Vaccine and Prevention CRS (Site ID: 30331), Seattle

02215

RECRUITING

Brigham and Women's Hospital (Site ID: 30007), Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Department of Health and Human Services

FED

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH